Ace the FPGEE 2025 for NABP: Unleash Your Pharmacist Potential!

A key disadvantage of Cost Effectiveness Analysis (CEA) is that the duration of studies required can be extensive. CEA often involves long-term outcomes, particularly when evaluating treatments for chronic conditions or diseases that require prolonged intervention to observe meaningful effects. Collecting data over long periods can complicate study design and increase the overall time needed to yield results.

Additionally, while the other aspects of CEA, such as its scope of treatment comparison, can be nuanced, the length of studies is a fundamental concern because it can delay decision-making and the implementation of beneficial interventions. It can also lead to challenges in maintaining participant adherence and reducing attrition rates, which affect the quality and reliability of the findings. Thus, the extensive duration required for studies makes it a significant disadvantage within the framework of CEA.